Bristol Stool Test support to explore potential dysbiosis in children with epilepsy
Antonella Riva¹, Alberto Preda¹, Maria Stella Vari¹, Francesca Marchese¹, Ganna Balagura¹, Vincenzo Salpietro¹,², Luigi Francesco Iannone², Vincenzo Belcastro³, Rita Citraro², Cinzia Ferraris⁴, Alberto Verrotti⁵, Paolo Mainardi⁶, Carmen Giordano⁷, Federico Zara⁸, Carlo Minetti¹,², Emilio Russo², Pasquale Striano¹,²
riva.anto94@gmail.com
¹ Paediatric Neurology and Muscular Diseases Unit, Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, "G. Gaslini" Institute, Genova, Italy.
² Institution, country Science of Health Department, School of Medicine, University of Catanzaro, Catanzaro, Italy.
³ Neurology Unit, Department of Medicine, S. Anna Hospital, Como, Italy.
⁴ Human Nutrition and Eating Disorder Research Center, Department of Public Health, Experimental and Forensic Medicine, University of Pavia, Pavia, Italy.
⁵ Department of Pediatrics, University of L'Aquila, L'Aquila, Italy.
⁶ Kolfarma srl, Genova, Italy.
⁷ Department of Chemistry, Materials and Chemical Engineering “Giulio Natta”, Politecnico di Milano, Milano, Italy.
⁸ Laboratory of Neurogenetics, Istituto Gianna Gaslini, Genova, Italy.

Keywords: Gut-Brain-Microbiota axis; Epilepsy; Neuropsychiatric Disorders; Bristol Stool Test; Children

Background Gut-brain-microbiota (GBM) axis is a bidirectional communication pathway between gut bacteria and the central nervous system (CNS) that exerts an important influence on key brain processes. Patients with neuropsychiatric disorders often show abnormal intestinal microbiota, according with disease severity. We evaluated epileptic patients by using the Bristol Stool Test (BST), a commonly used tool to assess potential GBM dysfunction.

Methods We enrolled children with epilepsy of different aetiology including subjects with neuropsychiatric comorbidities (intellectual disability, autism spectrum disorder, movement disorders) and healthy controls. Clinical data including gastrointestinal (GI) discomfort (abdominal pain, constipation, diarrhea, reflux, bloating, dyspepsia) were collected referring to Rome IV Criteria.

Results: A total of 148 individuals (mean age: 9,4±3,9 SD) were recruited. Patients group included 30 children with isolated epilepsy (IE) and 54 with complicated epilepsy (Epi+). Controls group included 64 individuals (mean age: 9,4±3,1 SD). BST scores were abnormal in 5 patients from IE group and 26 patients from Epi+. Nine controls showed abnormal BST. BST scores were significantly abnormal in patients compared with controls (p=.0026) and in patients with Epi+ compared with IE patients (p=.0047). BST scores were compared between IE and Epi+ patients in monotherapy (p=.038). Finally, BST scores were compared between patients with or without GI discomfort (p=.0001).

Conclusions: BST is an easy, cost-free tool to evaluate the intestinal transit and may be a surrogate for indicating potential dysbiosis in epilepsy patients. Children with comorbidities could have deep imbalances of their GBM axis. Abnormal scores positively correlate with presence of GI discomfort. Antiepileptic treatment did not influence the risk for abnormal BST scores. Nevertheless, the relationship between abnormal BST scores and the degree of intestinal dysbiosis should be addressed by further research.

https://microbiotami.com/